Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasodilator therapy for asymptomatic aortic regurgitation
ACTRN12610000753055Phase 4Not yet recruiting
- Sponsor
- Heart Foundation of New Zealand
- Start
- Oct 2010
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of perindopril, candesartan and amlodipine in aortic insufficiency (AI) (2 arms), sponsored by Heart Foundation of New Zealand. Primary endpoint: Change in left ventricular end systolic volume. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
perindoprilcandesartanamlodipine
03
Conditions
aortic insufficiency (AI)
Beyond the preview
Go deeper on ACTRN12610000753055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000753055.